Twist offers new gene fragments to the synthetic biology market

By The Science Advisory Board staff writers

December 11, 2020 -- Twist Bioscience has launched its new clonal-ready gene fragments. The gene fragments, with and without adapters, can be used to rapidly build constructs and minimize the time and cost of screening for clones.

Twist's gene fragments begin as oligonucleotides synthesized on the company's semiconductor-based silicon platform. The oligonucleotides are then annealed with polymerase chain reaction (PCR)-amplified to produce double-stranded DNA fragments. The fragments are error-corrected through an enzymatic reaction process. The final products are ready-to-use gene fragments that are compatible with many applications including cloning, gene and protein expression, pathway and enzyme engineering, and enzyme optimization.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here